Trials in Houston, Texas
Here are the top 9 medical studies for colorectal cancer in Houston, Texas
Popular Filters
Phase 3 Trials
Chemotherapy
Vitamin D3 + Chemotherapy + Bevacizumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Hot Springs, Arkansas
This trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Chemotherapy
ctDNA Testing for Colon Cancer Treatment Prediction
Recruiting1 awardPhase 2 & 3
Hot Springs, Arkansas
This trial tests how well ctDNA testing in the blood predicts treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
Kinase Inhibitor
Encorafenib + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Houston, Texas
This trial is testing a new combination of drugs to treat colorectal cancer that has spread and has a certain type of abnormal gene. The new combination is encorafenib plus cetuximab, which will be taken either alone or with standard chemotherapy.
Alkylating agents
Nivolumab + Chemotherapy for Anal Cancer
Recruiting2 awardsPhase 3
Hot Springs, Arkansas
This trial is testing whether adding nivolumab to standard chemotherapy is more effective for patients with metastatic anal cancer. Nivolumab helps the immune system fight cancer, while chemotherapy kills or stops cancer cells from growing. Nivolumab has shown significant effectiveness in treating metastatic squamous cell carcinoma of the anal canal.
Trials With No Placebo
Chemotherapy
Vitamin D3 + Chemotherapy + Bevacizumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Hot Springs, Arkansas
This trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Monoclonal Antibodies
GEN1042 for Advanced Cancers
Recruiting1 awardPhase 1 & 2
Kingwood, Texas
This trial is testing a new drug called GEN1042 to see if it can help treat advanced cancer. It focuses on patients whose cancer has spread or is hard to treat. The goal is to find out if GEN1042 can safely reduce or stop tumor growth.
Chemotherapy
ctDNA Testing for Colon Cancer Treatment Prediction
Recruiting1 awardPhase 2 & 3
Hot Springs, Arkansas
This trial tests how well ctDNA testing in the blood predicts treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
Monoclonal Antibodies
Encorafenib + Cetuximab + Nivolumab for Colorectal Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing a combination of drugs to treat patients with colorectal cancer that has spread and cannot be removed by surgery. The drugs work by blocking enzymes needed for cell growth and by helping the body's immune system attack the cancer.
CAR T-cell Therapy
IDE196 Combinations for Solid Tumors
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing the safety and effectiveness of a new drug, IDE196, for patients with solid tumors that have a specific gene mutation. The trial has three parts. First, they will test different doses of the drug to see what is safe and what the side effects are. Second, they will test the drug combination with binimetinib to see if it is effective and has any new side effects. Third, they will test the drug combination with crizotinib to see if it is effective and has any new side effects.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.